The following pages link to Pharmaceutical Statistics (Q76682):
Displaying 50 items.
- Sample size calculation for logrank test and prediction of number of events over time (Q76683) (← links)
- Assessing efficacy in important subgroups in confirmatory trials: An example using Bayesian dynamic borrowing (Q85936) (← links)
- Two‐stage phase II survival trial design (Q86701) (← links)
- Distribution of the two-samplet-test statistic following blinded sample size re-estimation (Q88687) (← links)
- Sample size recalculation for binary data in internal pilot study designs (Q88690) (← links)
- Survival trial design and monitoring using historical controls (Q89007) (← links)
- Sequential design approaches for bioequivalence studies with crossover designs (Q91173) (← links)
- Use of historical control data for assessing treatment effects in clinical trials (Q96784) (← links)
- How can we make better graphs? An initiative to increase the graphical expertise and productivity of quantitative scientists (Q100047) (← links)
- A stochastically curtailed two‐arm randomised phase II trial design for binary outcomes (Q101300) (← links)
- Delayed treatment effects, treatment switching and heterogeneous patient populations: How to design and analyze RCTs in oncology (Q108613) (← links)
- A critical review of graphics for subgroup analyses in clinical trials (Q108894) (← links)
- Model averaging for treatment effect estimation in subgroups (Q112660) (← links)
- Robust exchangeability designs for early phase clinical trials with multiple strata (Q114902) (← links)
- Decision rules for identifying combination therapies in open‐entry, randomized controlled platform trials (Q114916) (← links)
- Equal-tailed confidence intervals for comparison of rates (Q117958) (← links)
- Subgroup‐specific dose finding in phase I clinical trials based on time to toxicity allowing adaptive subgroup combination (Q121634) (← links)
- Missing data sensitivity analysis for recurrent event data using controlled imputation (Q127210) (← links)
- Improved inference for MCP‐Mod approach using time‐to‐event endpoints with small sample sizes (Q159462) (← links)
- Time‐to‐event calibration‐free odds design: A robust efficient design for phase I trials with late‐onset outcomes (Q5976479) (← links)
- Adaptive designs for IVPT data with mixed scaled average bioequivalence (Q5977410) (← links)
- Optimal planning of phase II/III programs for clinical trials with multiple endpoints (Q5978237) (← links)
- Bayesian MCPMod (Q5978526) (← links)
- TITE‐gBOIN: Time‐to‐event Bayesian optimal interval design to accelerate dose‐finding accounting for toxicity grades (Q5979400) (← links)
- Standard and reference‐based conditional mean imputation (Q5979690) (← links)
- Publication:86701 (← links)
- Publication:108894 (← links)
- Publication:100047 (← links)
- Publication:5978237 (← links)
- Publication:91173 (← links)
- Publication:96784 (← links)
- Publication:76683 (← links)
- Publication:159462 (← links)
- Publication:101300 (← links)
- Publication:108613 (← links)
- Publication:85936 (← links)
- Publication:88687 (← links)
- Publication:88690 (← links)
- Publication:112660 (← links)
- Publication:121634 (← links)
- Publication:89007 (← links)
- Publication:114902 (← links)
- Publication:114916 (← links)
- Publication:127210 (← links)
- Publication:117958 (← links)
- Publication:5976479 (← links)
- Publication:5977410 (← links)
- Publication:5979400 (← links)
- Publication:5979690 (← links)
- Publication:5978526 (← links)
